Clinical Study of Trilinolein Cream for Prevention of Relapse in Remission of Moderate-to-severe … (NCT06463353) | Clinical Trial Compass
Not Yet RecruitingNot Applicable
Clinical Study of Trilinolein Cream for Prevention of Relapse in Remission of Moderate-to-severe Atopic Dermatitis.
376 participantsStarted 2024-06-15
Plain-language summary
This multicenter, randomized, double-blind, placebo-controlled will be conducted at Yueyang Hospital of Integrative Medicine, Shanghai University of Traditional Chinese Medicine; Seventh People's Hospital, Shanghai University of Traditional Chinese Medicine; Jiading District Hospital of Traditional Chinese Medicine, Shanghai; and Baoshan District Hospital of Integrative Medicine, Shanghai; Huashan Hospital affiliated with Fudan University, Longhua Hospital affiliated with Shanghai University of Traditional Chinese Medicine, Shuguang Hospital affiliated with Shanghai University of Traditional Chinese Medicine, and the First Affiliated Hospital of the Naval Medical University. Approximately 376 participants will be recruited and randomly assigned to the Trilinolein cream or cream base group using block group randomization. The primary outcome will be time to relapse (number of days from the start of dosing to the time of relapse rating), and secondary outcomes will include eczema area and severity indices, overall investigator ratings, visual itch analog scores, dermatologic quality of life indices, overall improvement rates, and safety metrics. All data from the study will be analyzed using the SPSS 23.0 statistical package.
Who can participate
Age range2 Years – 75 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion criteria
✓. Patients with a clear diagnosis of atopic dermatitis in accordance with the diagnostic criteria of Chinese and Western medicine;
✓. Age ≥2 years and ≤75 years; gender is not limited;
✓. Patients with a previous history of moderate to severe atopic dermatitis (EASI score ≥ 8, or SCORAD score ≥ 26, or IGA score ≥ 3);
✓. Patients were in AD remission with a skin lesion IGA score ≤ 1 for 2 consecutive weeks;
✓. All patients or guardians signed an informed consent form, of which the guardian signed the informed consent form for patients aged 2-8 years (\<8); the patient and guardian signed the informed consent form for patients aged 8-18 years (\<18); and the patient signed the informed consent form for patients aged 18-75 years.
Exclusion criteria
✕. Patients who are in the acute morbid stage and have erosion, exudation, and secondary infection;
✕. Patients who are allergic to the test article and its components;
✕. Patients who are currently participating in other clinical studies or have participated in other clinical studies within 1 month;
What they're measuring
1
Recurrence time
Timeframe: Assessed at screening period -14 ~ -1 days (V1), treatment period day 1 (V2), week 4 ± 3 days (V3), week 8 ± 3 days (V4), week 12 ± 3 days (V5) and follow-up period week 16 ± 3 days (V6)
Trial details
NCT IDNCT06463353
SponsorShanghai Yueyang Integrated Medicine Hospital
✕. Patients with skin diseases other than AD in the area to be treated;
✕. Patients with severe hepatic or renal diseases, hematologic disorders, autoimmune diseases, chronic severe infections, diabetes or diseases of God, drug or alcohol abuse;
✕. Suffering from malignant tumors or other serious diseases that may affect the correct assessment of efficacy;
✕. Have been treated with dupliyuzumab with a discontinuation time ≤ 12 weeks, or have been treated with a JAK inhibitor with a discontinuation time ≤ 1 week;
✕. Patients who have been systematically treated with hormones, other immunosuppressive agents (cyclosporine, methotrexate, reglanoside, etc.) or phototherapy;